Johnson & Johnson / Ambrx Biopharma Inc.

Metastatic Castration-Resistant Prostate Cancer

35K US cases/yr · $12.0B Global Prostate Cancer Market (2025E)

Disease Overview

ARX517 is a site-specific PSMA-targeted ADC for mCRPC using Ambrx synthetic biology. Potential first-and-best-in-class. Platform includes ARX788 (HER2+) and ARX305 (RCC).

Competitive Landscape

mCRPC: AR-pathway agents, Pluvicto (RPT), taxanes. PSMA-ADC is differentiated from radiopharmaceuticals.

Renal Cell Carcinoma / Hematologic Malignancies (CD70)

Competitive Landscape

ARX305 is a site-specific CD70-targeted ADC in Phase 1 development for clear-cell RCC and CD70-expressing hematologic malignancies. The competitive landscape groups by MOA class: CD70-targeted ADCs (direct), CD70 monoclonal antibodies, anti-CD70 CAR-T cell therapies, and incumbent RCC standard-of-care agents. In the CD70 ADC class, Seagen's SGN-CD70A (MMAF payload) and Biogen Idec/AbbVie's vorsetuzumab mafodotin (SGN-75) were both discontinued after Phase 1 due to ocular and thrombocytopenia toxicities, leaving the class commercially undervalidated. In the CD70 mAb class, Celldex's cusatuzumab (ARGX-110) was evaluated in Phase 2 AML in partnership with J&J but development was deprioritized in 2021; Argenx retains residual rights. In the CD70-targeted CAR-T class, Allogene's ALLO-316 (allogeneic anti-CD70 CAR-T, Phase 1 RCC) and Crispr Therapeutics' CTX130 (Phase 1 RCC and T-cell lymphoma) are the most advanced, both demonstrating preliminary clear-cell RCC responses. In RCC standard of care, the IO+TKI combination backbones dominate: Merck's Keytruda + Pfizer's Inlyta (axitinib), BMS' Opdivo + Exelixis' Cabometyx (cabozantinib), and BMS' Opdivo + Yervoy (nivolumab + ipilimumab) represent the first-line market, with Merck/Eisai's Keytruda + Lenvima (lenvatinib) also approved. Commercial takeaway: CD70 is a validated-target, class-troubled MOA; ARX305 must prove ADC chemistry solves prior payload-toxicity failures to displace CAR-T and IO+TKI incumbents.

HER2+ Breast Cancer (ADC)

Competitive Landscape

ARX788 is a site-specific HER2-targeted antibody-drug conjugate using Ambrx's non-natural amino acid conjugation platform, coupled to a monomethyl auristatin F (MMAF) payload, in Phase 2/3 development for HER2+ metastatic breast cancer. The competitive landscape groups by MOA class: HER2-directed ADCs (the dominant class), HER2-directed monoclonal antibodies, HER2-directed tyrosine kinase inhibitors, and HER2 bispecifics. In the HER2 ADC class, AstraZeneca/Daiichi Sankyo's Enhertu (trastuzumab deruxtecan, DXd topo1 payload, FDA-approved 2019 HER2+ mBC and 2022 HER2-low mBC) is the category-defining product, generating approximately $3.8B in 2024 sales and is considered the first-line standard post-taxane. Roche's Kadcyla (ado-trastuzumab emtansine, DM1 payload, approved 2013) remains an adjuvant and 2L option, approximately $2.5B 2023 sales. Chinese-market competitors include Remegen's Aidixi (disitamab vedotin, vedotin MMAE payload, NMPA approved 2021 for gastric and urothelial) and BioAtla/Chinese biotech HER2 ADCs in Phase 2. In the HER2 mAb class, Herceptin (trastuzumab) biosimilars and Perjeta (pertuzumab) dominate foundational care. In the HER2 TKI class, Puma's Nerlynx (neratinib), Seagen/Pfizer's Tukysa (tucatinib), and Lilly's Tyverb (lapatinib, generic) complete standard of care. Zymeworks/Jazz's Ziihera (zanidatamab, HER2 bispecific) was approved 2024 for HER2+ biliary. Commercial takeaway: ARX788 enters behind Enhertu in a category where payload differentiation (MMAF vs DXd) and conjugation chemistry must deliver a narrow therapeutic index win to justify share.